From NASH to MASH: Current Market Dynamics in Hepatology

Back Bay Life Science Report

Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

1y ago 28:19

MP3•에피소드 홈

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.

The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”

Other topics in this podcast include:

Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay
How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market
Payer monographs and what’s required for hepatology drugs
The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization
Which companies are active in the rare liver disease space and how they differentiate themselves

Thank you for listening. You can find previous episodes of the podcast here.

We’d love to hear from you. Ask questions and submit your feedback.

32 에피소드